17 . 05 . 2016

Xeltis late-breaking data at AATS set stage for the development of first bioabsorbable heart valve

AATS annual meeting 2016 logo_smallOne-year follow-up results from pediatric feasibility study of Xeltis bioabsorbable cardiovascular pulmonary graft have been presented as a late-breaker at the 96th American Association of Thoracic Surgery (AATS) annual meeting today.

All five children, aged 4 to 12 years at study enrollment, had only one functioning heart ventricle as a result of congenital heart defects and showed significant improvement in their general conditions one year after surgery. The 12-month data also showed anatomical and functional stability of the graft and no device-related adverse events.

The success of this feasibility trial paved the way for Xeltis to develop a bioabsorbable pulmonary heart valve, which will enter clinical trials in Europe in 2016.

Read Press Release (ENGLISH) (DUTCH) (FRENCH) (GERMAN)

Learn more about the Xeltis Technology

View the full AATS press release

Go back